scispace - formally typeset
Journal ArticleDOI

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

J. W. Langston, +3 more
- 25 Feb 1983 - 
- Vol. 219, Iss: 4587, pp 979-980
Reads0
Chats0
TLDR
It is proposed that this chemical selectively damages cells in the substantia nigra in patients who developed marked parkinsonism after using an illicit drug intravenously.
Abstract
Four persons developed marked parkinsonism after using an illicit drug intravenously. Analysis of the substance injected by two of these patients revealed primarily 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) with trace amounts of 1-methyl-4-phenyl-4-propionoxy-piperidine (MPPP). On the basis of the striking parkinsonian features observed in our patients, and additional pathological data from one previously reported case, it is proposed that this chemical selectively damages cells in the substantia nigra.

read more

Citations
More filters
Journal ArticleDOI

Depletion of PINK1 affects mitochondrial metabolism, calcium homeostasis and energy maintenance

TL;DR: A key role for PINK1 is demonstrated in the regulation of mitochondrial homeostasis and energy metabolism under physiological conditions, and the impairment in energy maintenance was confirmed in the brain of Pink1-knockout mice by in vivo bioluminescence imaging.
Journal ArticleDOI

Vesicular monoamine transporters: Structure‐function, pharmacology, and medicinal chemistry

TL;DR: In this paper, a review summarizes the current understanding of the structure-function relationships of VMAT2, and the role of VAT2 on addiction and psychostimulant induced neurotoxicity.
Journal ArticleDOI

Neuroprotective Effect of Ghrelin in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson’s Disease by Blocking Microglial Activation

TL;DR: The data indicate that ghrelin may act as a survival factor for dopaminergic neurons by functioning as a microglia-deactivating factor and suggest that gh Relin may be a valuable therapeutic agent for neurodegenerative diseases such as PD.
Journal ArticleDOI

In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?

TL;DR: Each animal model based on alpha-synuclein overexpression reproduces a subset of features of PD and can be used to identify therapeutic targets and test disease-modifying therapies, but the predictive value remains speculative in the absence of effective neuroprotective treatments for PD in humans.
Journal ArticleDOI

Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease.

TL;DR: Current advances in therapeutic efforts for PD that aim to produce a disease-modifying therapy by targeting the spread, production, aggregation, and degradation of alpha-synuclein are reviewed.
References
More filters
Journal ArticleDOI

Chronic Parkinsonism secondary to intravenous injection of meperidine analogues.

TL;DR: Biogenic amines and metabolites in the cerebrospinal fluid and microscopic evaluation of the brain at necropsy were consistent with damage to aminergic neurons in the substantia nigra.
Journal ArticleDOI

Apraxia of lid opening

TL;DR: Apraxia of lid opening is a nonparalytic motor abnormality characterized by the patient's difficulty in initiating the act of lid elevation and differs from paralytic ptosis by being present only momentarily at the start of lidOpening.
Related Papers (5)